Clearside Biomedical (CLSD)
(Delayed Data from NSDQ)
$1.22 USD
+0.03 (2.52%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $1.22 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth A Momentum F VGM
Brokerage Reports
Clearside Biomedical, Inc. [CLSD]
Reports for Purchase
Showing records 221 - 240 ( 273 total )
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; Next: NDA Submission for ME-NIU by YE:18
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
NDA Submission on Track for ME-NIU by YE; Reiterate OP but Reducing PT to $4
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
AAO Data Highlights XIPERE ?s Differentiated Clinical Profile in Our View
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Attractive Value in Front of Multiple Near-Term Potential Catalysts
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Unclassified
Company: Clearside Biomedical, Inc.
Industry: Unclassified
Top-Line RVO Data for Phase 3 SAPPHIRE Trial Remains On- Track for Q4:18
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Clearside Biomedical, Inc.
Industry: Unclassified
Exploratory DME Phase 2 Hits Non-inferiority; Anticipate Next Steps in 2018
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Unclassified
Exploratory DME Phase 2 Hits Non-inferiority; Anticipate Next Steps in 2018
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Clearside Biomedical, Inc.
Industry: Unclassified
HULK versus TYBEE for DME: We See Near-Term Upside from Phase 2 Results
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Unclassified
Week Ahead
Provider: WEDBUSH SECURITIES INC.
Company: Clearside Biomedical, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Clearside Biomedical, Inc.
Industry: Unclassified
Q1 Financials and First NDA Submission for CLS-TA in Q4:18
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Unclassified
Suprachoroidal CLS-TA to Advance on Multiple Fronts in 2018
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Clearside Biomedical, Inc.
Industry: Unclassified
Company: Clearside Biomedical, Inc.
Industry: Unclassified
Sweet Fruit from the PEACHTREE-ME-NIU Phase 3 Hits
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L